TB (especially in a patient who cannot take oral rifampicin); leprosy; multiple-resistant staphylococcal infections such as staphylococcal pneumonia and osteomyelitis.
Dose: For treatment of TB in adult with body mass less than 50kg - 450 mg OD, body mass over 50 kg - 600 mg OD (max daily dose is 1.2 g). Treatment of TB in children > 3 years of age: 10 mg/kg OD or BD (maximum dose: 450 mg). For treatment of infectious diseases caused by the drug-sensitive microorganisms: daily dose for adults - 450-900 mg/day and for children 8-10 mg/kg of body mass BD or TID
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It selectively inhibits DNA-dependent RNA-polymerase.
Monitor LFTs and FBC in case of the prolonged treatment period; impaired liver functions; undernourished patients.
Allergy to rifamycin or any excipient of the formulation; chronic renal failure; pulmonary heart disease; jaundice; hepatitis; pregnancy; lactation.
Nausea; vomiting; diarrhea; hematopoietic disorders; headache, and ataxia.
Drug interactions: (It induces the cytochrome enzyme system); reduction of activity of warfarin, corticosteroids, cyclosporine, cardiac glycosides, oral hypoglycaemics, dapsone, narcotics analgesics, methadone, barbiturate, benzodiazepines, calcium channel blockers, beta-blockers, ketoconazole, ACE blockers, and doxycycline. Rifamycin SV, on an old chemical entity, was produced by the modification of Rifamycin B (which is inactive). It was later modified into Rifampicin (which is orally active)